Burning Rock Biotech Limited Sponsored ADR

BNR Healthcare Diagnostics & Research

Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024.

Revenue
−4.22%
EPS
−98.4%
Free cash flow
+46.0%
Total debt
−5.02%

Quarter to June 2026, against a year earlier

13.10 0.15 −1.13%
Market cap
$116.5M
P/E
0.0×
Fwd P/E
11.1×
Dividend yield
—
F-score
5/9
Altman Z
−2.95
Beneish M
−2.47
Dividend safety
n/a

Burning Rock Biotech Limited Sponsored ADR (BNR) P/E ratio

Alert me on P/E ratio

Burning Rock Biotech Limited Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
23 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
BNR Burning Rock Biotech Limited Sponsored ADR n/m
MYGN Myriad Genetics, Inc. compare n/m
BDSX Biodesix, Inc. compare n/m
IMDX Insight Molecular Diagnostics Inc. compare n/m
QUCY Quantum Cyber N.V compare n/m
FLGT Fulgent Genetics, Inc. compare n/m
XGN Exagen Inc. compare n/m
PRPO Precipio, Inc. compare n/m
MDXHF MedX Health Corp. compare n/m
Diagnostics & Research industry median 34.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BNR